TRENTON, N.J. (AP) — Biotech hulk Amgen Inc. pronounced Tuesday that a first-quarter distinction rose 5 percent on aloft sales of a tip dual drugs and dual new ones, and it simply kick Wall Street forecasts.
The builder of biologic drugs such as Enbrel for rheumatoid arthritis pronounced net income was $1.18 billion, or $1.48 per share, adult from $1.13 billion, or $1.20 per share, a year ago.
Excluding one-time items, a Thousand Oaks, Calif., association pronounced it would have warranted $1.29 billion, or $1.61 per share.
Revenue totaled $4.05 billion, adult 9 percent, notwithstanding neatly revoke sales for dual drugs with new reserve warnings.
Analysts were awaiting gain per share of $1.46, incompatible one-time items, and sales of $3.93 billion, according to FactSet.
“It’s not unequivocally a good entertain that it looks like during initial blush,” pronounced Edward Jones researcher Judson Clark, observant that practiced income was adult usually 2 percent. “This positively isn’t a fast-growing biotech association it was a few years ago.”
UBS researcher Matthew Roden remarkable a association surpassed researcher expectations even though a boost it got from dual one-time payments from investigate partners, totaling $72 million.
“It does leave one doubt if this kind of opening is sustainable,” Roden said, though called it “a good quarter.”
Amgen shares were prosaic during $68.63 in after-hours trading, after rising 34 cents during unchanging trade hours.
Outgoing CEO Kevin Sharer, who is being transposed by Chief Operating Officer Bob Bradway on May 23, told analysts a company’s sales, profit, drug tube and business growth were all clever in a quarter.
Sharer also praised Amgen owner George Rathmann, who died Sunday.
“His scholarship base, his enterprise to make large bets on projects that can pierce a needle … his energy, will always be partial of us,” Sharer pronounced of Rathmann.
Amgen, a world’s biggest biotechnology company, spent $723 million in a entertain on investigate and growth on an adjusted basis, adult 3 percent, as a few of a initial drugs are now in costly late-stage studious testing.
Sales and executive losses rose 5 percent on an practiced basement to $1.06 billion, especially since a association has started ads targeting consumers for a initial time and increasing a selling abroad for dual of a products: Enbrel and one of a company’s newest products, injected osteoporosis drug Prolia.
“I consider what we’re saying is them removing forward of biosimilars,” pronounced Clark.
The initial biosimilar versions of formidable biologic drugs are approaching to be authorized for U.S. sales in a subsequent few years, erasing their corner and slicing their sales only as general pills revoke sales of brand-name ones.
Clark pronounced he thinks Amgen is perplexing to build name approval forward of that for a dual products, that are some-more expected than Amgen’s other products to be requested by patients.
The Enbrel TV commercials underline golfer Phil Mickelson, while a Prolia commercials, that started recently, underline singer Blythe Danner worrying about “breaking a leg” as she goes on theatre for a performance.
Sales rose 9 percent in a entertain to $1.34 billion for Neulasta and Neupogen, for treating a decrease of infection-fighting white blood cells caused by cancer and other disorders. Enbrel sales jumped 7 percent to $938 million, and sales of 3 smaller drugs climbed by double-digit percentages.
Prolia and a identical drug, Xgeva for preventing fractures in carcenogenic bones, both saw sales some-more than triple from a tiny bottom to a total $241 million.
But a pointy sales decrease continued for blockbuster anemia drugs Aranesp and Epogen, that have had boundary put on dosing and payment due to reserve concerns. Epogen was down 17 percent to $446 million and Aranesp fell 11 percent to $518 million.
Amgen reiterated a 2012 practiced distinction foresee of $5.90 to $6.15 per share. Analysts envision $6.08 per share, on average.
__________
Linda A. Johnson can be followed during http://twitter.com/LindaJ_onPharma
Article source: http://news.yahoo.com/amgen-1q-profit-5-pct-beats-wall-street-203503578--finance.html
R Soft Web Hosting